Meet Oncologist Daniel Petrylak, MD

Meet Oncologist Daniel Petrylak, MD

Prostate Cancer | Daniel P Petrylak, MDПодробнее

Prostate Cancer | Daniel P Petrylak, MD

Daniel Petrylak, MD, explains the effect of second antigen spread in mCRPC patientsПодробнее

Daniel Petrylak, MD, explains the effect of second antigen spread in mCRPC patients

Daniel P. Petrylak, MD invites you to the 15th Annual NYGU™ Conference on March 11-12Подробнее

Daniel P. Petrylak, MD invites you to the 15th Annual NYGU™ Conference on March 11-12

Daniel Petrylak, MD, on investigating atezolizumab and cabozantinib relating to prostate cancerПодробнее

Daniel Petrylak, MD, on investigating atezolizumab and cabozantinib relating to prostate cancer

Novel agents and precision medicine in prostate cancer careПодробнее

Novel agents and precision medicine in prostate cancer care

Daniel P. Petrylak, MD, regarding PD-L1 biomarkers in the treatment of bladder cancerПодробнее

Daniel P. Petrylak, MD, regarding PD-L1 biomarkers in the treatment of bladder cancer

Daniel P. Petrylak, MD, on the role of DNA repair gene mutations in metastatic urothelial carcinomaПодробнее

Daniel P. Petrylak, MD, on the role of DNA repair gene mutations in metastatic urothelial carcinoma